title: [The prognostic influence of primary tumour and region of the affected spinal segment in 217 surgical patients with spinal metastases of different entities].
abstract: OBJECTIVE
  A retrospective study to evaluate the prognostic influence of the primary tumour and the anatomic level of spinal metastases was carried out.
  
  
  METHODS
  Between January 1984 and May 2005, 217 patients were surgically treated because of spinal metastases. The prognostic influence for the survival was analysed for the entity of the primary tumour and the localisation of the spinal metastases.
  
  
  RESULTS
  The median survival of the study group was 8.0 months (range: 0-191.5 months). Mamma carcinoma was the most frequent primary tumour with 62 cases (28.6 %). The spinal level of the metastases did not influence the postoperative survival (p = 0.9058). The entity of the primary tumour showed a significant influence for the postoperative survival (p < 0.0001).
  
  
  CONCLUSIONS
  In spinal metastases, the entity of the primary tumour was of prognostic value; the localisation of the spinal metastases at different spinal levels did not influence the postoperative survival. Therefore, the evaluation of the primary tumour is mandatory for an estimation of the expected survival.
authors.affiliation: Orthopädische Universitätsklinik Ulm, RKU, Ulm, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Ulmar
authors.forename: K
authors.initials: K
authors.lastname: Huch
authors.forename: T
authors.initials: T
authors.lastname: Kocak
authors.forename: S
authors.initials: S
authors.lastname: Catalkaya
authors.forename: U
authors.initials: U
authors.lastname: Naumann
authors.forename: S
authors.initials: S
authors.lastname: Gerstner
authors.forename: H
authors.initials: H
authors.lastname: Reichel
mesh_terms: D001943:Breast Neoplasms / Q000401:mortality / Q000601:surgery; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000556:secondary / Q000601:surgery; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000556:secondary / Q000601:surgery; D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000556:secondary / Q000601:surgery; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000556:secondary / Q000601:surgery; D002574:Cervical Vertebrae / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality / Q000601:surgery; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery; D008159:Lumbar Vertebrae / Q000601:surgery; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery; D008297:Male; D009382:Neoplasms, Unknown Primary / Q000401:mortality / Q000601:surgery; D009959:Oropharyngeal Neoplasms / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000601:surgery; D012189:Retrospective Studies; D013125:Spinal Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D016019:Survival Analysis; D013904:Thoracic Vertebrae / Q000601:surgery; D013964:Thyroid Neoplasms / Q000401:mortality / Q000601:surgery